课题基金 / 基金详情

SDMC: HIV Vaccine Trials Network

SDMC: HIV Vaccine Trials Network
SDMC:HIV 疫苗试验网络
批准号:
8782602
负责人:
Peter B. Gilbert
金额:
$1324.18万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-06-29 至 2020-11-30

项目摘要

项目成果

Peter B. Gilbert的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):本申请继续作为艾滋病毒疫苗试验网络(HVTN)的统计和数据管理中心(SDMC),是组成HVTN领导小组的三个申请之一。为了实现RFA-AI-12-012所述的总体科学目标,即开发安全有效的艾滋病毒疫苗,HVTN SDMC科学议程包括以下目标:目标1,提供高质量的安全数据管理和安全监测,并通过应用最佳数据和临床管理做法、遵守临床数据交换标准和实施最先进的技术,不断提高质量和效率;目的2:设计、监测和分析评估候选HIV疫苗方案安全性和免疫原性的疗效前试验;目标3:开发和实施用于测量疫苗的免疫分析数据处理和分析的工具和方法
英文摘要
DESCRIPTION (provided by applicant): This application to continue as the Statistical and Data Management Center (SDMC) for the HIV Vaccine Trials Network (HVTN) is one of three applications comprising the Leadership Group of the HVTN. To address the overall scientific goal described in RFA-AI-12-012, the development of a safe and effective HIV vaccine, the HVTN SDMC scientific agenda includes the following aims: Aim 1, to provide high quality secure data management and safety monitoring and to continually improve quality and efficiency by applying best data and clinical management practices, adhering to clinical data interchange standards, and implementing state-of-the-art technologies; Aim 2, to design, monitor, and analyze pre-efficacy trials that evaluate the safety and immunogenicity of candidate HIV vaccine regimens; Aim 3, to develop and implement tools and methods for data processing and analysis of immunological assays used for measuring vaccine immunogenicity; Aim 4, to refine and implement novel Phase 2b test-of-concept and Phase 3 licensure trial designs with primary objective to assess vaccine efficacy to prevent HIV infection; Aim 5, to refine and implement novel quantitative methods for assessing and developing immune correlates of protection against HIV infection and early biomarkers of disease progression for regimens showing efficacy; Aim 6, in collaboration with other NIAD networks, to account for non-vaccine prevention modalities in meeting the objectives of Aims 2 through 5 and to co-conduct combination regimen trials; Aim 7, to conduct clinical trials to assess monoclonal antibodies for HIV immunoprophylaxis and vaccines for TB and HCV. The SDMC has extensive experience in the design, conduct and analysis of global HIV vaccine and prevention studies. The systems we propose to use for data collection, management, monitoring and analysis are well-tested, in accordance with GCDMP, 21 CFR Part 11 and GCP, and will comply with CDISC Standards. In addition, SDMC statisticians and computational biologists will develop novel quantitative methodologies to increase efficiency, rigor, and scientific incisiveness of the proposed program of HIV vaccine trials. RELEVANCE: 34 million people globally are estimated to be living with HIV, and 2.7 million new infections occur annually (2011 UNAIDS). Despite recent advances in biomedical interventions that reduce the risk of HIV acquisition, eliminating the pandemic will require a safe and effective HIV vaccine. Only through human clinical trials held to the highest scientific, ethical and regulatory standards will the goal of an HIV vaccine be realized.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CoVPN Cross-Protocol Analyses
CoVPN 5001 - A prospective study of acute immune responses to SARS-CoV-2 infection
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals
海外基金